CDXS vs GEVO vs VERO vs BEAM

For growth investors, Gevo, Inc.

(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -15. 1% for Venus Concept Inc. (VERO). Analysts rate Codexis, Inc. (CDXS) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Beam Therapeutics Inc.

(BEAM) delivered a total return of -55. 6%, compared to -99. 9% for Venus Concept Inc. (VERO). Over 10 years, the gap is even starker: BEAM returned +67. 8% versus VERO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Venus Concept Inc.

(VERO) is the lower-risk stock at 1. 43β versus Codexis, Inc. 's 2. 31β — meaning CDXS is approximately 61% more volatile than VERO relative to the S&P 500. On balance sheet safety, Beam Therapeutics Inc. (BEAM) carries a lower debt/equity ratio of 24% versus 15% for Venus Concept Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Gevo, Inc.

(GEVO) is pulling ahead at 849. 3% versus -15. 1% for Venus Concept Inc. (VERO). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to -869. 0% for Venus Concept Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gevo, Inc.

(GEVO) is the more profitable company, earning -21. 1% net margin versus -72. 5% for Venus Concept Inc. — meaning it keeps -21. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GEVO leads at -11. 7% versus -274. 6% for BEAM. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Venus Concept Inc.

(VERO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Codexis, Inc. (CDXS) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VERO: -100. 0%, CDXS: -19. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CDXS (Healthcare) and GEVO (Basic Materials) and VERO (Healthcare) and BEAM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CDXS is a small-cap high-growth stock; GEVO is a small-cap high-growth stock; VERO is a small-cap quality compounder stock; BEAM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.